Synapse
⌘+K
Sign In
Sign Up for Free
Synapse
Sign In
Sign Up for Free
Home
Communities
Explore
More
Language
English
English
Seagen (Canada)
h-index: 31
Total citations: 6,669
Total papers: 92
Homepage:
https://www.seagen.com
Recent papers from Seagen (Canada)
Redefined Core Competencies for Genetic Counselors in Canada to Reflect an Evolving Workforce
Journal of Genetic Counseling · 2026
Discovery of a Novel Tripeptide Linker that Broadens the Therapeutic Window of Auristatin-Based Antibody–Drug Conjugates by Reducing Bone Marrow Toxicity
Bioconjugate Chemistry · 2026
A Multivalent Pan-Ebolavirus Nanoparticle Vaccine Provides Protection in Rodents from Lethal Infection by Adapted Zaire and Sudan Viruses
2025
Predictors of brain metastases in patients with oligometastatic solid tumours treated with stereotactic body radiation therapy
2024
Microtubule-dependent orchestration of centriole amplification in brain multiciliated cells
2024
Microtubule-dependent orchestration of centriole amplification in brain multiciliated cells
2024
Abstract PO1-04-07: Disitamab vedotin, a clinical stage HER2-directed antibody-drug conjugate, shows potent antitumor activity as a monotherapy and in combination with tucatinib in preclinical breast cancer models
Cancer Research · 2024
Machine Learning–Based Survival Prediction Models for Progression-Free and Overall Survival in Advanced-Stage Hodgkin Lymphoma
JCO Clinical Cancer Informatics · 2024
L2086F Mutant ROS1-Rearranged NSCLC Resistant to Repotrectinib Responds to Cabozantinib: A Case Report
JTO Clinical and Research Reports · 2024
Physician frontline treatment preferences for stage III/IV classic Hodgkin lymphoma: the real-world US CONNECT study
Future Oncology · 2023
Understanding Treatment Patterns and Outcomes among Patients with De Novo Unresectable Locally Advanced or Metastatic Urothelial Cancer: A Population-Level Retrospective Analysis from Alberta, Canada
Current Oncology · 2022
Accuracy and Safety of Novel Designs for Phase I Drug-Combination Oncology Trials
Statistics in Biopharmaceutical Research · 2022
2021 White Paper on Recent Issues in Bioanalysis: Mass Spec of Proteins, Extracellular Vesicles, CRISPR, Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Rare Matrices; Regulatory Inputs ( Part 1A – Recommendations on Endogenous Compounds, Small Molecules, Complex Methods, Regulated Mass Spec of Large Molecules, Small Molecule, PoC & Part 1B - Regulatory Agencies' Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell Therapy and Vaccine)
Bioanalysis · 2022
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
Annals of the Rheumatic Diseases · 2022
Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study
Journal of Clinical Oncology · 2021
Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR
Annals of Surgery · 2021
In Defense of TNT: A Dynamite Strategy
Journal of Clinical Oncology · 2021
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Journal of Clinical Oncology · 2019
Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors
Journal of Clinical Oncology · 2019
Brentuximab Vedotin: A Nursing Perspective on Best Practices and Management of Associated Adverse Events
Clinical journal of oncology nursing · 2018